About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 422 record(s)
Req # A-2020-001429
Adverse Reaction Reports (AERs). Report numbers: E2B_02956799, E2B_02956801, E2B_02956802, E2B_02956803, E2B_02956804, E2B_02956805, E2B_02956807, E2B_02957187, E2B_02957853, E2B_02958256, E2B_02958375, E2B_02958410, E2B_02958512, E2B_02959491, E2B_02959602, E2B_02959751, E2B_02959752, E2B_02959753, E2B_02959756, E2B_02959762.Organization: Health Canada
June 2021
Req # A-2020-001243
Adverse Reaction Reports (AERs). Report numbers: E2B_02560838, E2B_02560944, E2B_02560960, E2B_02561148, E2B_02561373, E2B_02561666, E2B_02561822, E2B_02561936, E2B_02562249, E2B_02562344, E2B_02562572, E2B_02562580, E2B_02562643, E2B_02563246, E2B_02563248, E2B_02563252, E2B_02563694, E2B_02563862, E2B_02563876, E2B_02563879.Organization: Health Canada
June 2021
Req # A-2020-001369
Adverse Reaction Reports (AERs) for HYDROCHLOROTHIAZIDE, IRBESARTAN. Report numbers: 000737765, E2B_03140090.Organization: Health Canada
June 2021
Req # A-2020-001009
Adverse Reaction Reports (AERs) for LEUPROLIDE ACETATE. Report numbers: E2B_02867961, E2B_02874464, 000731055, 000733375, E2B_02874150.Organization: Health Canada
June 2021
Req # A-2020-001067
Adverse Reaction Reports (AERs). Report numbers: 000730225, 000730336, 000730354, 000730355, 000730357, 000730383, 000730464, 000730718, 000730763, 000730844, 000731298, 000731315, 000731804, 000731965, 000732325, 000732448, 000732813, 000732819, 000732874, 000732981.Organization: Health Canada
June 2021
Req # A-2020-000992
Adverse Reaction Reports (AERs). Report numbers: E2B_01066202, E2B_01107793, 000686872, 00949997, 000598431, E2B_01077314, 000598431, 000694839, 000695075, E2B_01077314.Organization: Health Canada
June 2021
Req # A-2020-000903
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-109376-836.Organization: Health Canada
June 2021
Req # A-2020-001795
Adverse Reaction Reports (AERs) for Diclectin (doxylamine succinate / pyridoxine hydrochloride). Report numbers: E2B_03409197, E2B_03502689, E2B_03502960, E2B_03502967.Organization: Health Canada
June 2021
Req # A-2020-001886
Adverse Reaction Reports (AERs) for Mesalazine. Report numbers: 927207, 929367, 0929765, 926934, 928754, 927030, 927787, 927173, 926591, 925935.Organization: Health Canada
June 2021
Req # A-2020-001443
Adverse Reaction Reports (AERs) for DOCETAXEL. Report numbers: 912494, 912544, 913311, 914722, 914781, 915869, E2B_03015124, E2B_03037091, E2B_03127152, E2B_03144247, E2B_03167805, E2B_03134684, E2B_03144553, E2B_03070750.Organization: Health Canada
June 2021